Table 3.
Summary of patients affected by disorders commonly related to opioids at baseline and during treatment with prolonged-release oxycodone/naloxone (OXN-PR)
| Symptoms | Patients, n (%)
|
||||
|---|---|---|---|---|---|
| Baseline | T7 | T15 | T45 | P-valuea | |
| Nausea and vomiting | 0 | 2 | 0 | 1 | NS |
| Pruritus | 1 | 0 | 0 | 0 | NS |
| Drowsiness | 2 | 2 | 2 | 1 | NS |
| Mouth dryness | 2 | 2 | 0 | 0 | NS |
| Vertigo | 1 | 0 | 0 | 0 | NS |
| Hyperhidrosis | 3 | 0 | 1 | 0 | NS |
Note:
a
Cochran’s Q test for changes in frequencies from day 0 to day 45.
Abbreviations: NS, not statistically significant; T7, T15, and T45, respectively, 7-, 15-, and 45-day treatment with OXN-PR.